Impact of Tumor LINE-1 Methylation Level and Neoadjuvant Treatment and Its Association with Colorectal Cancer Survival
Open Access
- 11 November 2020
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 10 (4), 219
- https://doi.org/10.3390/jpm10040219
Abstract
Recent studies suggest that long-interspersed nucleotide element-1 (LINE-1) hypomethylation is commonly found in colorectal cancer (CRC), and is associated with worse prognosis. However, the utility of LINE-1 methylation on the prognosis of CRC is still controversial, and may be due to the fact that some clinical and pathological features may affect LINE-1 methylation. Thus, the aim of this study was to assess the prognostic value of tumor LINE-1 methylation in CRC, through their association with the CRC clinical and pathological characteristics. Survival of sixty-seven CRC patients was evaluated according to the median of tumor LINE-1 methylation, as well as pathological and oncological variables. We also studied the association between LINE-1 methylation and pathological features, and finally, we assessed the overall and disease-free survival of LINE1 methylation, stratified by neoadjuvant treatment and further checked by multivariate Cox regression to assess the statistical interactions. LINE-1 was hypomethylated in the CRC tumor with respect to the tumor adjacent-free area (p < 0.05), without association with any other clinical and oncological features, nor with overall and disease-free survival rates for CRC. Relevantly, in neoadjuvant treatment, LINE-1 methylation was associated with survival rates. Thus, disease-free and overall survival rates of treated CRC patients were worse in the hypomethylated LINE-1 tumors than those with normal LINE-1 methylation (p = 0.004 and 0.0049, respectively). Indeed, LINE-1 was hypermethylated more in the treated patients than in the non-treated patients (p < 0.05). The present study showed that tumor LINE-1 hypomethylation was associated with worse survival rates in only treated patients. Our data suggest an interactive effect of neoadjuvant treatment and tumor LINE-1 methylation, which could be a specific-tissue biomarker to predict survival of the treated patients, and help to personalize treatment in CRC.This publication has 27 references indexed in Scilit:
- Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patientsClinical Epigenetics, 2016
- Serum 25-Hydroxyvitamin D and Adipose Tissue Vitamin D Receptor Gene Expression: Relationship With Obesity and Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2015
- Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer PrognosisJNCI Journal of the National Cancer Institute, 2014
- Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancerBritish Journal of Cancer, 2013
- LINE-1 Hypomethylation During Primary Colon Cancer ProgressionPLOS ONE, 2011
- Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcriptionOncogene, 2010
- The impact of retrotransposons on human genome evolutionNature Reviews Genetics, 2009
- Evaluation of Methods for the Measurement of Low-Density Lipoprotein CholesterolJournal of Cardiovascular Pharmacology and Therapeutics, 2005
- Antisense Promoter of Human L1 Retrotransposon Drives Transcription of Adjacent Cellular GenesMolecular and Cellular Biology, 2001
- Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia, 1985